Clinical study of early inhalation of Budesonide in the prevention of bronchopulmonary dysplasia in very low birth weight infants

Abstract

Objective To investigate the preventive and adverse effects of postnatal inhalation of Budesonide in early stage on bronchopulmonary dysplasia (BPD) in very low birth weight infants. Methods A total of 105 cases of high risk premature infants with BPD, who were born in the Neonatal Intensive Care Unit (NICU) from Shenzhen Maternity and Child Healthcare Hospital from July 15, 2015 to December 25, 2016, and their gestational age ≥27 weeks and < 32 weeks or birth weight ≥1 000 g and <1 500 g were collected for a prospective randomized controlled trial, and were randomly divided into 3 groups: early inhalation group(34 cases), late inhalation group(34 cases) and non-inhalation group(37 cases). The oxygen time, and the incidence of BPD, periventricular-intraventricular hemorrhage(IVH), retinopathy of prematurity (ROP), necrotizing enterocolitis of the newborns (NEC), patent ductus arteriosus in preterm infants (PDA), sepsis and hyperglycemia of infants in 3 groups were compared. Results The average oxygen time in early inhalation group was 9 days, while in late inhalation group and the non-inhalation group was 15 days and 18 days, respectively.The average oxygen time in early inhalation group was significantly lower than that in the late inhalation group and the non-inhalation group, with the difference being statistically significant (H=6.09, P 0.05). Conclusions Postnatal inhalation of Budesonide in early stage in high risk very low birth weight infants can reduce the incidence of BPD and the oxygen time, and the adverse reactions are not obvious. Key words: Infant, premature; Very low birth weight infant; Bronchopulmonary dysplasia; Glucocorticoid; Budesonide; Inhalation